SERD Therapeutics Market Competitive Analysis Research Report and Explosive Growth Opportunity, Developments Forecast By 2031

The market size of SERD Therapeutics is estimated to be 1508.0 million in 2022 and is expected to increase to 6382.2 million by 2031, with a compound annual growth rate (CAGR) of 17.5% during the forecast period of 2023-2031.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1246

The high prevalence of breast cancer primarily drives the SERD therapeutics market, the increasing demand for SERD therapies, and the growing number of clinical trials. Furthermore, the SERD therapeutics market will experience growth due to the rapid adoption of advanced medical technologies, population growth, and increasing health-conscious individuals. Nevertheless, the market's growth is hindered by the high cost of devices, the complexity of procedures, and the resistance to endocrine therapy. Additionally, lockdowns have positively and negatively affected the SERD therapeutics market during the COVID-19 pandemic.

Major key Players in the SERD therapeutics market are

• Teva Pharmaceutical Industries Ltd.
• Zenopharm LLC.
• Zentalis Pharmaceuticals
• Genentech
• Olema Pharmaceuticals
• G1 Therapeutics, Inc.
• Glenmark Pharmaceuticals
• HBT Labs, Inc
• Hoffmann-La Roche AG
• InventisBio
• Amneal Pharmaceuticals Inc
• AstraZeneca, Plc.
• Sun Pharma Advanced Research Company
• Shandong Luoxin Pharmaceutical
• Zeno Alpha
• Atossa Therapeutics
• Evestra
• Reddy's Laboratories
• Eli Lilly and Company
• Novartis AG
• Radius Health
• Sanofi S.A.
• Aragon Pharmaceuticals

Recent Key Developments:

• In June 2021, Eli Lilly and Company announced new findings regarding the exploratory use of Verzenio® (abemaciclib) in high-risk early breast cancer, as well as its oral selective oestrogen receptor degrader (SERD) LY3484356 (ASCO). In a subset of patients with HR+, HER2-, high-risk early breast cancer (EBC) who had undergone neoadjuvant chemotherapy, Lilly is releasing an exploratory analysis from the positive Phase 3 monarch study. This study tested Verzenio, a CDK4/6 inhibitor.
• In September 2020, InventisBio announced the successful completion of a $147 million series D fundraising campaign, which was supported by several of the world's most prominent biopharmaceutical and healthcare venture capital firms. Three medicinal compounds are presently in various stages of clinical development at InventisBio, and a new product has recently commenced a global phase I clinical trial. In comparison to other oral SERDs in clinical development worldwide, D-0502 demonstrated exceptional anti-tumor efficacy in phase 1 research, along with an acceptable safety profile and superior absorQption.
• In September 2019, G1 Therapeutics, Inc. published preliminary data from a Phase 1/2a dose-escalation trial of G1T48, an oral selective oestrogen receptor degrader (SERD), in patients with oestrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. G1T48 was well tolerated in the study and demonstrated anti-tumor efficacy in patients who had received a significant amount of pretreatment. A first-line Phase 3 pivotal trial is anticipated to commence in 2020, and the results of this trial provide support for the future development of G1T48 in both first-line and adjuvant settings.

Get Enquiry For Before Buying Here https://www.insightaceanalytic.com/enquiry-before-buying/1246

Drugs that downregulate the estrogen receptor are classified as selective estrogen receptor degraders (SERDs). SERD and full receptor antagonist are indispensable therapeutic alternatives for HR-positive breast cancer. Tamoxifen, a specific estrogen receptor modulator (SERM) with receptor agonist and antagonist action, and aromatase inhibitors, which prevent estrogen production but induce acquired resistance, are examples of endocrine medications. Fulvestrant, the sole SERD that is currently licensed, exhibits mild drug-like characteristics. The improvement of disease management has been primarily focused on the development of oral SERDs with optimal target occupancy and potency, as well as improved clinical performance. It is anticipated that the SERD therapeutics market will experience growth during the forecast period as a result of the increasing investments made by key participants in the development of promising breast cancer therapies.

The North American region is the primary revenue generator in this market at the regional level, as a result of the increasing prevalence of breast cancer, the growing awareness of SERD therapies, and the increasing government investment in the research and development of therapies for the treatment of various cancer diseases. In contrast, the European region will also dominate the market during the forecast period as a result of the increasing prevalence of chronic diseases, stringent regulations, and advancements in the biopharmaceutical field. The Asia-Pacific market is anticipated to experience substantial development in the future as a result of the rapid adoption of new technologies and the expansion of SERD therapeutic industries.

Order this Premium Report: https://www.insightaceanalytic.com/buy-report/1246

The foremost manufacturers in this field emphasise developing innovative SERD therapies, forging new partnerships, collaborations, and agreements, raising awareness of SERD therapies, and increasing research investments to advance technology. These strategies will accelerate their market expansion prospects. In 2020, QLHC announced an evaluation of Sanofi's SAR439859, an oral estrogen receptor degrader (SERD), in a novel I-SPY 2 study arm that was designed to evaluate patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. In 2018, AstraZeneca initiated phase 1 of its next-generation oral SERD, AZD9833. AstraZeneca has rapidly expanded and advanced the development of AZD9833 even though work on AZD9496 stalled after a few early clinical trials. AstraZeneca initiated the enrollment of patients in the phase 3 clinical trial of AZD9833 late last month.

Market Segments

Market Size & Forecasts and Trend Analyses, based on Products
• Giredestrant (GDC-9545)
• Imlunestrant (LY3484356)
• Faslodex
• Elacestrant
• Camizestrant (AZD9833)
• Other Pipeline Products
Market Size & Forecasts and Trend Analyses, based on Route Of Administration
• Subcutaneous
• Parenteral
• Intramuscular
• Oral
• Infusion
• Other
Market Size & Forecasts and Trend Analyses, based on Indication
• ESR1-mutated advanced or metastatic breast cancer
• ER-positive
• HER2-negative
• Other

Market Size & Forecasts and Trend Analyses, based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America SERD therapeutics market revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada
Europe SERD therapeutics market revenue by Country,
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific SERD therapeutics market revenue by Country,
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America SERD therapeutics market revenue by Country,
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa SERD therapeutics market revenue by Country,
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Details insights on this market: @ https://www.insightaceanalytic.com/report/global-serd-therapeutics-market/1246

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

This release was published on openPR.